[go: up one dir, main page]

BRPI0713031B8 - composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos - Google Patents

composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos

Info

Publication number
BRPI0713031B8
BRPI0713031B8 BRPI0713031A BRPI0713031A BRPI0713031B8 BR PI0713031 B8 BRPI0713031 B8 BR PI0713031B8 BR PI0713031 A BRPI0713031 A BR PI0713031A BR PI0713031 A BRPI0713031 A BR PI0713031A BR PI0713031 B8 BRPI0713031 B8 BR PI0713031B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
compound
pyran
dihydro
antitumor
Prior art date
Application number
BRPI0713031A
Other languages
English (en)
Inventor
Rodríguez Vicente Alberto
Francesch Solloso Andrés
Murcia Pérez Carmen
Sánchez Sancho Francisco
Fernando Reyes Benítez José
Coello Molinero Laura
Garranzo García-Ibarrola María
del Carmen Cuevas Marchante María
Jesús Martín López Mª
Fernández Rodríguez Rogelio
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BRPI0713031A2 publication Critical patent/BRPI0713031A2/pt
Publication of BRPI0713031B1 publication Critical patent/BRPI0713031B1/pt
Publication of BRPI0713031B8 publication Critical patent/BRPI0713031B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

composto antitumoral, processo para obtenção deste, composição farmacêutica que o compreende e uso deste. são proporcionados compostos antitumorais obtidos a partir de poríferos, da família raspailiidae, gênero lithoplocamia, espécie lithistoides e derivados dos mesmos.
BRPI0713031A 2006-06-16 2007-06-15 composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos BRPI0713031B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06380173 2006-06-16
EP06380173.2 2006-06-16
PCT/EP2007/055959 WO2007144423A1 (en) 2006-06-16 2007-06-15 Antitumoral dihydropyran-2-one compounds

Publications (3)

Publication Number Publication Date
BRPI0713031A2 BRPI0713031A2 (pt) 2013-03-12
BRPI0713031B1 BRPI0713031B1 (pt) 2020-10-06
BRPI0713031B8 true BRPI0713031B8 (pt) 2021-05-25

Family

ID=38508885

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0722429-0A BRPI0722429A2 (pt) 2006-06-16 2007-06-15 Processo para a preparação de um composto de di-hidropiran-2-ona, processo para a preparação de compostos intermediários, e compostos de fragmentos
BRPI0713031A BRPI0713031B8 (pt) 2006-06-16 2007-06-15 composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0722429-0A BRPI0722429A2 (pt) 2006-06-16 2007-06-15 Processo para a preparação de um composto de di-hidropiran-2-ona, processo para a preparação de compostos intermediários, e compostos de fragmentos

Country Status (29)

Country Link
US (2) US8324406B2 (pt)
EP (3) EP2404913A3 (pt)
JP (2) JP5117491B2 (pt)
KR (1) KR101474031B1 (pt)
CN (2) CN102336730A (pt)
AR (1) AR061506A1 (pt)
AT (1) ATE522514T1 (pt)
AU (1) AU2007259257B8 (pt)
BR (2) BRPI0722429A2 (pt)
CA (1) CA2654334C (pt)
CY (1) CY1112103T1 (pt)
DK (1) DK2032551T3 (pt)
ES (1) ES2371942T3 (pt)
HR (1) HRP20110845T1 (pt)
IL (1) IL195676A (pt)
MX (1) MX2008015754A (pt)
MY (1) MY145788A (pt)
NO (2) NO341508B1 (pt)
NZ (1) NZ573706A (pt)
PL (1) PL2032551T3 (pt)
PT (1) PT2032551E (pt)
RS (1) RS52034B (pt)
RU (2) RU2444519C2 (pt)
SG (1) SG174830A1 (pt)
SI (1) SI2032551T1 (pt)
TW (2) TW201213316A (pt)
UA (1) UA97369C2 (pt)
WO (1) WO2007144423A1 (pt)
ZA (1) ZA200810315B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080769A1 (en) 2007-12-20 2009-07-02 Pharma Mar, S.A. Antitumoral compounds
MX2010008922A (es) 2008-02-20 2010-09-07 Actelion Pharmaceuticals Ltd Compuestos antibioticos azatriciclicos.
JP5404652B2 (ja) 2008-02-22 2014-02-05 アクテリオン ファーマシューティカルズ リミテッド オキサゾリジノン誘導体
RU2530884C2 (ru) 2008-10-07 2014-10-20 Актелион Фармасьютиклз Лтд Трициклические оксазолидиноновые антибиотические соединения
CN102164919B (zh) 2008-10-10 2014-04-09 埃科特莱茵药品有限公司 噁唑烷基抗生素
WO2010149688A2 (en) 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CN110790737B (zh) * 2019-11-07 2022-07-22 河南中烟工业有限责任公司 一种2,3-二氢-3,5-二羟基-6-乙基-4h-吡喃-4-酮的制备方法
KR20240093809A (ko) 2021-10-22 2024-06-24 파르마 마르, 에스.에이. 항종양 화합물
CN117510448A (zh) * 2023-11-13 2024-02-06 贵州中医药大学 一种二氢吡喃酮衍生物及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA938019B (en) * 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
EP0729464A1 (en) * 1993-11-19 1996-09-04 PARKE, DAVIS & COMPANY 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds

Also Published As

Publication number Publication date
AR061506A1 (es) 2008-09-03
JP2012021023A (ja) 2012-02-02
ZA200810315B (en) 2010-02-24
US8501968B2 (en) 2013-08-06
RU2444519C2 (ru) 2012-03-10
TW201213316A (en) 2012-04-01
EP2032551B1 (en) 2011-08-31
EP2404912A3 (en) 2012-07-25
EP2404912A2 (en) 2012-01-11
NZ573706A (en) 2011-09-30
CA2654334C (en) 2014-06-10
EP2404913A2 (en) 2012-01-11
DK2032551T3 (da) 2012-01-02
RS52034B (sr) 2012-04-30
PL2032551T3 (pl) 2012-01-31
HK1130052A1 (en) 2009-12-18
CA2654334A1 (en) 2007-12-21
NO20111248L (no) 2008-12-16
CN101679340B (zh) 2013-06-05
KR20090024261A (ko) 2009-03-06
UA97369C2 (ru) 2012-02-10
AU2007259257A1 (en) 2007-12-21
TW200811128A (en) 2008-03-01
US8324406B2 (en) 2012-12-04
EP2404913A3 (en) 2012-06-06
WO2007144423A1 (en) 2007-12-21
US20120190870A1 (en) 2012-07-26
AU2007259257A8 (en) 2012-04-05
PT2032551E (pt) 2011-12-06
IL195676A0 (en) 2009-09-01
CY1112103T1 (el) 2015-11-04
EP2032551B9 (en) 2012-02-29
RU2009101150A (ru) 2010-07-27
TWI373469B (en) 2012-10-01
CN101679340A (zh) 2010-03-24
AU2007259257B2 (en) 2011-12-08
CN102336730A (zh) 2012-02-01
EP2032551A1 (en) 2009-03-11
JP2009539943A (ja) 2009-11-19
SG174830A1 (en) 2011-10-28
HRP20110845T1 (hr) 2011-12-31
US20090186938A1 (en) 2009-07-23
US20100048690A2 (en) 2010-02-25
NO341508B1 (no) 2017-11-27
IL195676A (en) 2012-06-28
JP5117491B2 (ja) 2013-01-16
ATE522514T1 (de) 2011-09-15
MY145788A (en) 2012-04-30
ES2371942T3 (es) 2012-01-11
SI2032551T1 (sl) 2012-01-31
BRPI0722429A2 (pt) 2013-11-26
RU2011133128A (ru) 2013-02-10
KR101474031B1 (ko) 2014-12-17
BRPI0713031A2 (pt) 2013-03-12
AU2007259257B8 (en) 2012-04-05
MX2008015754A (es) 2009-01-12
NO20090054L (no) 2009-01-06
BRPI0713031B1 (pt) 2020-10-06

Similar Documents

Publication Publication Date Title
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
CL2007003299A1 (es) Compuestos derivados de macrociclos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007003797A1 (es) Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
BRPI0908637B8 (pt) composto e composição farmacêutica do mesmo
CL2008000065A1 (es) Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
BRPI0720972B8 (pt) compostos análogos de ciclopamina e composições farmacêuticas compreendendo os referidos compostos
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
EA200802008A1 (ru) Фармацевтические композиции
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
BRPI0818804A2 (pt) Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
BRPI0717822A2 (pt) Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto.
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2007001630A1 (es) Compuestos derivados de pirrolidinamida; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
BRPI0910288A2 (pt) composto de derivados de aminometil benzeno, composição farmacêutica que compreende esse composto e uso do mesmo.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: ESCLARECA A DIVERGENCIA NO NOME DA INVENTORA "MA JESUS MARTIN LOPEZ", CONSTANTE NA PUBLICACAO INTERNACIONAL WO2007/144423 A1, E O CONSTANTE NA PETICAO DE ENTRADA NA FASE NACIONAL, "MA JESUS MARTIN LOPES".

B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: EXIGENCIA ANULADA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/06/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2831 DE 08-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.